Immunoglobulins	O
associated	O
with	O
elevated	O
riboflavin	O
binding	O
by	O
plasma	B-Organism_substance
from	O
cancer	B-Cancer
patients	O
.	O

Plasma	B-Organism_substance
from	O
182	O
patients	O
with	O
different	O
malignant	B-Cancer
diseases	I-Cancer
was	O
tested	O
for	O
riboflavin	O
binding	O
by	O
immunoglobulins	O
,	O
which	O
have	O
been	O
recently	O
identified	O
as	O
major	O
carriers	O
of	O
this	O
micronutrient	O
.	O

A	O
wide	O
range	O
of	O
binding	O
(	O
5	O
.	O
9	O
to	O
130	O
pmole	O
/	O
ml	O
plasma	B-Organism_substance
)	O
was	O
observed	O
,	O
and	O
significant	O
elevations	O
were	O
found	O
for	O
patients	O
having	O
breast	B-Cancer
cancer	I-Cancer
(	O
21	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
melanoma	B-Cancer
(	O
25	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
compared	O
to	O
controls	O
(	O
15	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
)	O
.	O

The	O
proteins	O
responsible	O
for	O
a	O
majority	O
of	O
the	O
higher	O
binding	O
were	O
identified	O
as	O
immunoglobulins	O
,	O
based	O
on	O
their	O
elution	O
from	O
gel	O
filtration	O
columns	O
and	O
the	O
removal	O
of	O
57	O
-	O
88	O
%	O
of	O
the	O
non	O
-	O
albumin	O
binding	O
by	O
treating	O
of	O
plasma	B-Organism_substance
with	O
Protein	O
A	O
-	O
agarose	O
.	O

The	O
binding	O
was	O
only	O
weakly	O
related	O
to	O
the	O
total	O
concentration	O
of	O
immunoglobulins	O
(	O
r	O
=	O
0	O
.	O
11	O
by	O
linear	O
regression	O
analysis	O
)	O
,	O
however	O
,	O
and	O
is	O
apparently	O
due	O
to	O
a	O
subclass	O
that	O
is	O
elevated	O
in	O
some	O
types	O
of	O
cancer	B-Cancer
.	O

Elevated	O
levels	O
of	O
these	O
immunoglobulins	O
may	O
contribute	O
to	O
the	O
lower	O
urinary	B-Organism_substance
levels	O
and	O
clearance	O
of	O
riboflavin	O
in	O
cancer	B-Cancer
.	O

